^
Association details:
| Biomarker: | CD19 expression + TNFRSF17 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | AZD0120 (CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD19/BCMA Dual-Targeting Fastcar-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: An Update
Published date:
11/02/2023
Excerpt:
From October 2021 to June 2023, nine eligible refractory/ relapsed defuse large B cell lymphoma (r/r DLBCL) patients (pts) were enrolled in this study and treated with a single infusion of GC012F...The lymphoma samples of all patient expressed CD19, and 7 out of 8 expressed various levels of BCMA...This first-in-human trial of GC012F, a CD19-BCMA dual targeting CAR-T product, for the treatment of r/r B-NHL showed a manageable safety profile and promising clinical responses. The ORR was 100% at month 3 with 77.8% (7/9) achieving CR.
DOI:
10.1182/blood-2023-185476
Source:
Title:
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Published date:
05/25/2023
Excerpt:
From October 2021 to January 2023, nine eligible r/r DLBCL pts were enrolled and treated with a single infusion of GC012F in escalating dosing cohorts after a standard lymphodepletion regimen....All pt lymphoma samples expressed CD19, and 6 out of 7 expressed BCMA….This first-in-human trial of GC012F for the treatment of r/r B-NHL showed a manageable safety profile and promising clinical responses. The ORR was 100% at M3 with 77.8% (7/9) achieving CR.
DOI:
10.1200/JCO.2023.41.16_suppl.7562
